Skip to content

Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients.

Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients. Randomized Controlled Study

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05168865
Enrollment
0
Registered
2021-12-23
Start date
2023-08-01
Completion date
2024-04-01
Last updated
2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frozen Embryo Transfer, Hormone Replacement Therapy, Letrozole, Live Birth, Miscarriage, Polycystic Ovarian Disease

Brief summary

One of the indications of freezing is to reduce the risk of ovarian hyperstimulation syndrome particularly in polycystic ovarian disease (PCOS) women. Very few RCTs addressed the issue of optimizing the endometrium for a frozen cycle. Interestingly, Letrozole for ovarian stimulation showed significantly better reproductive outcome when compared with hormone replacement therapy (HRT) cycle. In addition, HRT cycle has been associated with higher miscarriage rate when compared with natural cycle frozen embryo transfer. Nevertheless, there is not yet a well-designed prospective randomized study comparing letrozole and HRT in PCOS women undergoing frozen embryo transfer.

Detailed description

Freezing oocytes and embryos has become an integral part of the daily IVF practice. One of the indications of freezing is to reduce the risk of ovarian hyperstimulation syndrome particularly in polycystic ovarian disease (PCOS) women. Very few randomized control trials addressed the issue of optimizing the endometrium for a frozen cycle. As PCOS women do not regularly ovulate, most of their frozen cycles are conducted after hormonal replacement therapy (HRT) preparation of the endometrium or after ovulation induction. In HRT cycle the endometrium is prepared using exogenous estradiol and progesterone. While HRT cycles requires less monitoring and easy scheduling, it is costly, associated with increased risk of thrombosis and women must continue using the exogenous hormones up to 10 to 12 weeks of gestation. Interestingly, Letrozole for ovarian stimulation showed significantly better reproductive outcome when compared with HRT cycles. In agreement with the previous Chinese study, a retrospective Japanese ART registry data that included 110 722 frozen cycles confirmed the superiority of letrozole. Nevertheless, there is not yet a well-designed prospective randomized study. In addition, HRT cycle has been associated with higher miscarriage rate when compared with natural cycle frozen embryo transfer. HRT is usually used in patients with PCOS. A retrospective study including 2664 PCOS patients showed significant decrease in the pregnancy loss when letrozole was used when compared with HRT in frozen cycles. Investigators thought of comparing letrozole and HRT in women with PCOS who are undergoing frozen cycles in PCOS women. Live birth and miscarriage rates will be the primary outcomes.

Interventions

DRUGLetrozole 2.5mg

Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.

Sponsors

Dubai Fertility Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Women with PCOS diagnosed with Rotterdam criteria. * Age between 20 to 40-year-old * Undergoing frozen oocytes intracytoplasmic sperm injection transfer or frozen embryo transfer * Willingly accept to participate in the study

Exclusion criteria

* Women \> 40 years old or younger than 20. * Uterine pathology that decreases the chance of pregnancy or increases risk of miscarriage such as * Uterine fibroids (sub-mucous of any size or intramural of \> 3 cm) * Uncontrolled endocrinal-pathological disease like * Cushing syndrome, * Adrenal hyperplasia, * Hyperprolactinemia, * Acromegaly, * Thyroid disease, * Diabetes mellitus, and * Immune disorders. * Presence of Hydrosalpinx * Not willing or able to sign the consent form.

Design outcomes

Primary

MeasureTime frameDescription
livebirth rate per embryo transfer9 monthsA birth after 24 weeks gestation with a baby showing signs of life.

Secondary

MeasureTime frameDescription
miscarriage rate per embryo transfer6 monthsloss of pregnancy before 24 weeks gestation
ongoing pregnancy per embryo transfer3 monthsongoing viable pregnancy (by ultrasound examination at 12 weeks' gestation)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026